Pfizer gets boost in landmark $1 billion pregabalin patent damages dispute
UK court sides with the drug company on key counterfactual assumptions in high-stakes compensation battle with the NHS and generics
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.